niagenbioscience.com (NAGE): Utang-utang marang kapitalisasi buku

Tandha merek Chromadex Corp (NAGE)

Chromadex Corp (NAGE) brings together leading experts in cellular aging, providing them with an advanced infrastructure and lucrative contracts. The business relies on its own laboratories and the oversight of Niagen component production, which stabilizes supplies. The price trend captured at 0.03 is complemented by the retention of biochemists through patent ownership and the targeted hiring of compliance specialists.

NAGE (ChromaDex Corp.) riwayat Utang marang nilai buku saka 20.03.2025 nganti 27.10.2026

Ringkesan rincian data analitis Chromadex Corp (NAGE)

- rega lan prakiraan konsensus rega:
Rega saham Niagen|NAGE - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Kapitalisasi pasar ChromaDex Corporation|NAGE - Rega Tumbas Perusahaan
- data kapitalisasi buku:
Nilai Buku saben Saham ChromaDex|NAGE - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku niagenbioscience.com|NAGE - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Chromadex Corp|NAGE - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas niagenbioscience.com|NAGE - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku ChromaDex Corporation
Analisis fundamental perusahaan:ChromaDex Corp.
Produk asli ChromaDex

For Chromadex Corp (NAGE), which is developing the longevity ingredients market, this indicator determines the degree of business dependence on borrowed funds relative to equity. By analyzing the ratio of debt to the company's book capitalization, an investor assesses the risk of insolvency: a decrease in this metric confirms the issuer's financial stability amid growing demand in the NAD+ sector, minimizing the probability of bankruptcy.

Karo sapa Chromadex Corp saingan

ISRG - Utang-utang marang kapitalisasi buku|Rasio utang marang nilai buku danaher.com DHR|Utang-utang marang kapitalisasi buku BDX (Becton Dickinson)|STE - Utang-utang marang aset resik|WST (West Pharmaceutical Services Inc) - Utang-utang marang kapitalisasi buku|Baxter Healthcare (BAX) - Utang marang nilai buku|MASI (Masimo Corporation) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku STVN|Rasio utang marang kapitalisasi buku Teleflex (TFX)|Rasio utang marang kapitalisasi buku Merit Medical Systems, Inc. MMSI|Utang marang nilai buku Envista Holdings Corp|Rasio utang marang aset resik ICU Medical Inc. ICUI|Utang-utang marang kapitalisasi buku XRAY (DENTSPLY SIRONA Inc.)|LMAT: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku AtriCure|STAA (STAAR Surgical Co.) - Rasio utang marang nilai buku|ZIMV: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik AngioDynamics Inc. (ANGO)|Utang marang nilai buku Cerus Corporation|Utang marang modal buku TKNO (teknova.com)|Rasio utang marang kapitalisasi buku Monogram Orthopedics|STSS - Rasio utang marang aset resik|InfuSystem Inc - Utang marang nilai buku|UTMD: Utang-utang marang kapitalisasi buku|KRMD (korumedical.com) - Rasio utang marang kapitalisasi buku|nyxoah.com (NYXH) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku MBOT (Microbot Medical)|Utang-utang marang nilai buku PDEX|Rasio utang marang kapitalisasi buku Zentek Limited ZTEK|Rasio utang marang nilai buku Elutia Corporation ELUT|Utang marang nilai buku Milestone Scientific (MLSS)|nexgel.com - Utang marang modal buku|Rasio utang marang kapitalisasi buku RVP (Retractable Tech)|HBIO - Utang-utang marang aset resik|FEMY (Femasys Corp) - Utang-utang marang kapitalisasi buku|Meihua Medical Technologies Co., Ltd. (MHUA) - Utang marang nilai buku|POAI - Utang-utang marang kapitalisasi buku|Rasio utang marang aset resik CJMB|Atrion (ATRI) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik NURO (NeuroMetrix Inc)